Pure Global
NCT06290388

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

A Phase 1/2a, Multicenter, Open-label, Dose Escalation and Expansion Study of Intravenously Administered 23ME-01473 in Participants With Advanced Solid Malignancies
23andMe, Inc.·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
23ME-01473
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
23andMe, Inc.
Location
San Antonio, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Mar 07, 2024
End date
Jun 30, 2026
Enrollment
82 participants
Primary outcome

Phase 1:Incidence and severity of dose-limiting toxicities (DLTs),Phase 1: Incidence and severity of adverse events (AEs),Phase 1 Incidence and severity of serious adverse events (SAEs),ORR based on investigator assessment against RECIST 1.1 criteria

Summary

This is a first-in-human open-label study to evaluate the safety, tolerability,
 pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by
 intravenous infusion in participants with advanced solid cancers who have progressed or are
 intolerant of available standard therapies.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06290388
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06290388 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by 23andMe, Inc. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 82 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.